Leading industry players, Sistemic and Roslin Cells, are going to work together with Scottish Development International (SDI) to make the process of undertaking clinical trials in cell therapy easier, faster and more successful in reaching commercial realisation.
Sistemic Limited (Sistemic), the miRNA profiling company with facilities in Glasgow, Scotland and Boston, announced today the signature of an agreement to allow Progenitor Cell Therapy (PCT) to initiate evaluation studies on Sistemic’s SistemQC™ stem cell characterisation technology.
Sistemic will be attending the 4th Cell Therapy Conference: Manufacturing and Testing of Pluripotent Stem Cells in June to highlight the development of SistemPSCCheck™ - the world’s first commercial assay for assessment of pluripotent stem cell contamination in derived cell therapy products
GLASGOW, SCOTLAND Sistemic will be attending Phacilitate Cell & Gene Therapy World and the World Stem Cell Summit in January to highlight the development of their assay for assessment of pluripotent stem cell contamination in derived cell therapy products
Glasgow, SCOTLAND. Sistemic Ltd. is excited to announce significant progress with the development of a miRNA-based assay for assessment of pluripotent stem cell (PSC) contamination in derived cell therapy products. The development is being undertaken in conjunction with LGC, the UK National Measurement Laboratory and Designated Institute for chemical and bio-measurement.
Glasgow, Scotland Sistemic Ltd announced today the award of an Innovate UK grant to further develop, to a market-ready stage, its groundbreaking prototype microRNA-based assay for accurate assessment of pluripotent stem cell contamination in derived cell therapy products.